Isoindoline Sigma-2 Antagonists for Aβ Synapse Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as cholinesterase inhibitors and memantine, offer only small and impermanent symptomatic improvements, and there is a lack of effective disease-modifying agents.
Innovation Solution
Isoindoline compounds that act as sigma-2 receptor functional antagonists inhibit the deleterious effects of soluble Aβ oligomers, preventing synaptic dysfunction and synapse loss by competing with Aβ oligomers for receptor binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved medications (cholinesterase inhibitors and memantine) are used for Alzheimer's disease treatment, then symptomatic improvement of cognition and function is achieved, but the effects are small and impermanent with no disease-modifying capability
Solution Approach 1:
The patent introduces an intermediary mechanism by targeting the sigma-2 receptor, which mediates the protective effects against Aβ oligomer toxicity. The isoindoline compounds act as sigma-2 receptor ligands to activate this protective pathway, representing an intermediary approach that differs from direct Aβ aggregation inhibition or cholinergic enhancement. This intermediary mechanism provides more sustained and reliable therapeutic effects.
Solution Approach 2:
The patent converts the harmful effect of Aβ oligomers into a beneficial therapeutic opportunity by identifying that sigma-2 receptor activation can protect against Aβ oligomer toxicity. Rather than simply blocking Aβ formation, the invention harnesses the cellular stress response pathway (sigma-2 receptor) that is activated in response to Aβ oligomer presence, transforming the harmful exposure into a protective mechanism.
2Adaptability or versatility
If current medications are used to treat Alzheimer's disease, then some symptomatic relief is provided, but there is a lack of disease-modifying agents that can alter disease progression
Solution Approach 1:
Instead of directly targeting Aβ pathology (the conventional approach), the patent inverts the strategy by targeting the cellular response to Aβ pathology. Rather than trying to eliminate Aβ oligomers, the invention activates the sigma-2 receptor pathway that provides cellular protection against Aβ oligomer toxicity, offering a disease-modifying approach that addresses the downstream protective mechanisms.
3Object-affected harmful factors
If isoindoline sigma-2 receptor antagonist compounds are administered, then Aβ oligomer-induced cellular toxicity is inhibited, but the compounds must selectively target sigma-2 receptor to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that confer selective affinity for the sigma-2 receptor subtype. The isoindoline core structure with specific substituent patterns (as defined in the patent's chemical formulas) creates localized interaction characteristics that preferentially engage sigma-2 receptor binding sites while minimizing interactions with other receptor families, thereby achieving selective protection against Aβ toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The isoindoline compounds effectively inhibit Aβ oligomer-induced cellular toxicity, providing a therapeutic approach to treat early stages of Alzheimer's disease and other neurodegenerative disorders.
Implementation Method 1
isoindoline compounds that bind to the sigma-2 receptor... that behave as functional neuronal antagonists exhibit pharmacological competition with Aβ oligomers
Data Source
AI summary
Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.